Asselah T, et al. - The goal of this research was to examine the efficacy of once-daily combination of elbasvir (EBR) 50 mg and grazoprevir (GZR) 100 mg, with and without ribavirin (RBV) in HCV genotype 4 (GT4)-infected subjects participating in phase 2/3 clinical program with EBR/GZR. It was demonstrated that the regimens of 12 weeks of EBR/GZR without RBV, and 16 weeks of EBR/GZR plus RBV, were effective among HCV GT4-infected treatment-naïve and treatment-experienced patients, respectively. Data also exhibited that baseline NS5A resistance-associated substitutions did not exert any influence on the efficacy of EBR/GZR in GT4-infected enrollees.